CTB Special Seminar: Frank McCormick, PhD, FRS, DSc (Hon) | “RAS proteins in human disease”

Please join us for a special CTB seminar with Dr. Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, on Friday, May 29, 2026, from 10:00 - 11:00 am.

Friday, May 29th, 10:00 - 11:00 am, HSW-303
Presentation Title: "RAS proteins in human disease"

Frank McCormick, PhD, is a Professor at the UCSF Helen Diller Family Comprehensive Cancer Center and holds the David A. Wood Chair of Tumor Biology and Cancer Research. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. In addition, Dr. McCormick’s group led to the identification of the CDK4 kinase inhibitor, Palbociclib, approved for treating advanced breast cancer. Dr. McCormick's current research interests center on ways of targeting Ras proteins and their regulators, including the NF1 protein neurofibromin.

Zoom Link: https://ucsf.zoom.us/j/93425761191?pwd=DrnncQ5fSt2Rv1LgHVS3oU0bQpqCx6.1
Meeting ID: 934 2576 1191
Passcode: 454913

Please contact [email protected] with questions.